Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06878170 · ClinicalTrials.gov registry record · Phase 1
A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers
A Phase 1 study of COVID-19, sponsored by Rock BioMedical.
- Active
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06878170 is a Phase 1 study of COVID-19 that is active but no longer recruiting, run by Rock BioMedical. The registered enrollment target is 60 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06878170, a Phase 1 study of COVID-19, is active but no longer recruiting, sponsored by Rock BioMedical.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers
Conditions Studied
Interventions
- BIOLOGICAL RBM-001
Study Locations (1)
Florida
- QPS Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2026-01-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06878170
The ClinicalTrials.gov registry entry for NCT06878170 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is Rock BioMedical, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which RBM-001 is the first listed.
NCT06878170 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06878170 about?
NCT06878170 is a clinical study titled "A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers". A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers
What is the current status of trial NCT06878170?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2024-09-30. Estimated completion is 2026-01-30.
What conditions does trial NCT06878170 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT06878170?
The interventions under investigation include: RBM-001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06878170?
This trial is sponsored by Rock BioMedical, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06878170 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
RECRUITING · Phase 1
-
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
RECRUITING · Phase 1
-
A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.
RECRUITING · Phase 1
-
Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET)
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.